PATENT

1949 WHAT IS CLAIMED IS:

- 1. A method of treating cholinergic controlled secretions including excessive sweating, lacrimation and mucus secretion, said method comprising administering to the patient a therapeutically effective amount of Botulinum toxin type A in order to reduce the secretion.
- 2. The method according to claim 1 wherein the Botulinum toxin type A is administered to the patient's nerve plexus in an amount of between about 0.01 and about 50 units.
- 3. The method according to claim 1 wherein the Botulinum toxin type A is administered to the patient's ganglion in an amount of between about 0.01 and about 50 units.
- 4. The method according to claim 1 wherein the Botulinum toxin type A is administered to the patient's spinal cord in an amount of between about 0.01 and about 50 units.
- 5. The method according to claim 1 wherein the Botulinum toxin type A is administered to the patient's central nervous system in an amount of between about 0.01 and about 50 units.
- 6. A method for relieving pain associated with smooth muscle disorders, including spasms in the sphincters of the cardiovascular arteriole, gastro-intestinal system, urinary, gall bladder and rectum, said method comprising administering to the patient a

5

5

PATENT

therapeutically effective amount of Botulinum toxin type A in order to relieve pain.

- 7. The method according to claim 6 wherein the Botulinum toxin type A is administered to the patient's pyloric valve in an amount between about 1 and about 50 units.
- 8. A method for treating smooth muscle disorders, including spasms in the sphincters of the cardiovascular arteriole, gastrointestinal system, urinary, gall bladder and rectum, said method comprising administering to the patient a therapeutically effective amount of Botulinum toxin type A in order to lessen the spasms.

5

5

- 9. The method according to claim 8 wherein the Botulinum toxin type A is administered to the patient's pyloric valve in an amount between about 1 and about 50 units.
- 10. A method for relieving pain associated with smooth muscle disorders, including spasms in the lower gastrointestinal muscles and rectum, said method comprising administering to the patient a therapeutically effective amount of Botulinum toxin type A in order to relieve pain.
- 11. The method according to claim 10 wherein the Botulinum toxin type A is administered to the patient's lower colon in an amount between about 0.01 and about 50 units.
- 12. A method for relieving pain associated with smooth muscle disorders, including spasms in the

-23- PATENT

sphincters lower gastrointestinal muscles and rectum, said method comprising administering to the patient a therapeutically effective amount of Botulinum toxin type A in order to lessen the spasms.

- 13. The method according to claim 12 wherein the Botulinum toxin type A is administered to the patient's lower colon in an amount between about 0.01 and about 50 units.
- 14. A method for relieving pain associated with muscle spasms in conditions secondary to sports injuries, said method comprising administering to a patient a therapeutically effective amount of a Botulinum toxin of a type having short duration activity in order to relieve pain.
- 15. The method according to claim 14 wherein the Botulinum toxin comprises Botulinum toxin type F.
- 16. The method according to claim 15 wherein the therapeutic amount comprises a dose of between about 1 and about 10 units.
- 17. The method according to claim 16 wherein the muscle spasms occur in a patient's thigh and the Botulinum toxin is administered into the thigh
- 18. A method for relieving pain associated with contractions in arthritis, said method comprising administering to a patient a therapeutically effective amount of a Botulinum toxin in order to relieve pain.
- 19. A method for treating swallowing disorders, including spasms, said method comprising administering

5

5

5

to the patient a therapeutically effective amount of Botulinum toxin type A.

-24-

10

20. A method for treating tension headache comprising administering to the patient a therapeutically effective amount of Botulinum toxin type A.

ADD) A2